Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 569

The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.

Prognostically relevant gene signatures of high-grade serous ovarian carcinoma

Open access
Verhaak, Roel G.W., Tamayo, Pablo, Yang, Ji-Yeon, Hubbard, Diana, Zhang, Hailei, Creighton, Chad J., Fereday, Sian, Lawrence, Michael, Carter, Scott L., Mermel, Craig H., Kostic, Aleksandar D., Etemadmoghadam, Dariush, Saksena, Gordon, Cibulskis, Kristian, Duraisamy, Sekhar, Levanon, Keren, Sougnez, Carrie, Tsherniak, Aviad, Gomez, Sebastian, Onofrio, Robert, Gabriel, Stacey, Chin, Lynda, Zhang, Nianxiang, Spellman, Paul T., Zhang, Yiqun, Akbani, Rehan, Hoadley, Katherine A., Kahn, Ari, Köbel, Martin, Huntsman, David, Soslow, Robert A., Defazio, Anna, Birrer, Michael J., Gray, Joe W., Weinstein, John N., Bowtell, David D., Drapkin, Ronny, Mesirov, Jill P., Getz, Gad, Levine, Douglas A., Meyerson, Matthew, The Cancer Genome Atlas Research Network·2012·Journal of Clinical Investigation

Abstract

Because of the high risk of recurrence in high-grade serous ovarian carcinoma (HGS-OvCa), the development of outcome predictors could be valuable for patient stratification. Using the catalog of The Cancer Genome Atlas (TCGA), we developed subtype and survival gene expression signatures, which, when combined, provide a prognostic model of HGS-OvCa classification, named "Classification of Ovarian Cancer" (CLOVAR). We validated CLOVAR on an independent dataset consisting of 879 HGS-OvCa expression profiles. The worst outcome group, accounting for 23% of all cases, was associated with a median survival of 23 months and a platinum resistance rate of 63%, versus a median survival of 46 months and platinum resistance rate of 23% in other cases. Associating the outcome prediction model with BRCA1/BRCA2 mutation status, residual disease after surgery, and disease stage further optimized outcome classification. Ovarian cancer is a disease in urgent need of more effective therapies. The spectrum of outcomes observed here and their association with CLOVAR signatures suggests variations in underlying tumor biology. Prospective validation of the CLOVAR model in the context of additional prognostic variables may provide a rationale for optimal combination of patient and treatment regimens.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci65833

Cites

51 of 51 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 51 references

Cited by

See all 569

Metadata

Authors
Verhaak, R. G. W., Tamayo, P., Yang, J.-Y., Hubbard, D., Zhang, H., Creighton, C. J., Fereday, S., Lawrence, M., Carter, S. L., Mermel, C. H., Kostic, A. D., Etemadmoghadam, D., Saksena, G., Cibulskis, K., Duraisamy, S., Levanon, K., Sougnez, C., Tsherniak, A., Gomez, S., Onofrio, R., Gabriel, S., Chin, L., Zhang, N., Spellman, P. T., Zhang, Y., Akbani, R., Hoadley, K. A., Kahn, A., Köbel, M., Huntsman, D., Soslow, R. A., Defazio, A., Birrer, M. J., Gray, J. W., Weinstein, J. N., Bowtell, D. D., Drapkin, R., Mesirov, J. P., Getz, G., Levine, D. A., Meyerson, M., & The Cancer Genome Atlas Research Network
Venue
Journal of Clinical Investigation
Published
2012-12-21
Volume
123
Issue
1
Pages
517-25
ISSN
0021-9738 (ISSN-L)
OpenAlex
W2031674672
Cited by
569
References
51
FWCI
35.97
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. https://app.cochat.ai/papers/10.1172/jci65833
The paper
Verhaak, R. G. W., Tamayo, P., Yang, J.-Y., Hubbard, D., Zhang, H., Creighton, C. J., Fereday, S., Lawrence, M., Carter, S. L., Mermel, C. H., Kostic, A. D., Etemadmoghadam, D., Saksena, G., Cibulskis, K., Duraisamy, S., Levanon, K., Sougnez, C., Tsherniak, A., Gomez, S., . . . The Cancer Genome Atlas Research Network. (2012). Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. Journal of Clinical Investigation. https://doi.org/10.1172/jci65833

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.